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Abstract Using antibody against the Rho binding domain of
ROKK, two neuronal phosphoproteins of 62 and 80 kDa were
co-immunoprecipitated from brain extracts. Peptide analysis re-
vealed their identity as collapsin response mediator proteins
(CRMPs); p62 was CRMP-2 whereas p80 was a novel splice
form of CRMP-1 with an extended N-terminus. p80 CRMP-1
was able to complex with CRMP-2, suggesting that p80
CRMP-1 and CRMP-2 form oligomers. CRMP-2 was the ma-
jor substrate of ROK. p80 CRMP-1 interacted with the kinase
domain of ROKK, resulting in inhibition of the catalytic activity
towards other substrates. Over-expression of p80 CRMP-1 and
CRMP-2 together counteracted the e¡ects of RhoA on neurite
retraction, an e¡ect enhanced by mutation of the ROK phos-
phorylation site in CRMP-2. p80 CRMP-1 and CRMP-2 may
be modulators of RhoA-dependent signaling, through interaction
with and regulation of ROKK.
/ 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The Rho GTPases regulate neuronal morphology by in£u-
encing the stability and assembly of the actin cytoskeleton
[1,2]. They mediate signaling pathways that respond to up-
stream signals and studies on ¢broblasts and other cells
have revealed cross-talk amongst Rho GTPases, resulting in
either a hierarchical linear cascade [3] or antagonistic e¡ects
of Rho and Rac activities [4]. In neuronal cells, activation of
Rac/Cdc42 and antagonism of RhoA signaling appears to be
implicated in neurite outgrowth [5], suggesting that counter-
balancing of Rac and RhoA signaling is essential for forming
complex neuronal morphology [2]. The activity of RhoA ef-
fector kinases ROKs (Rho kinases) has been shown to play a
key role in regulating neurite outgrowth [5^7], probably
through multiple e¡ects on the dynamic changes in various
cytoskeletal components [8]. An involvement of Rho GTPase
in semaphorin 3A (Sema3A)-mediated axonal guidance and
growth cone motility has also been demonstrated (see [9] for
review). Rac1 was ¢rst shown to act downstream of Sema3A
in dorsal root ganglion neurons where dominant negative
Rac1 inhibited growth cone collapse [10]. Antibodies against
a member of the collapsin response mediator proteins
(CRMPs), a family of dihydropyrimidinase-related neuronal
proteins involved in axonal outgrowth [11^13], can also block
Sema3A-induced growth cone collapse [14], suggesting that
CRMP-2 may play a role downstream of the Sema3A recep-
tor, neuropilin 1 and its co-receptor plexin A1 [15]. Recently it
has been shown that Rac1 interacts directly with the plexin B1
cytoplasmic tail [16^18] indicating that some receptor sub-
types may engage directly with the Rho GTPase pathways.
Furthermore, clustering of the cytoplasmic domain of the co-
receptor results in RhoA activation and actin contractility
[18]. Drosophila plexin B has also been shown to both inhibit
Rac-GTP and signal through Rho [19], possibly via PDZ
RhoGEFs, which interact speci¢cally with plexin B family
members [20]. We have found that CRMP-2 in combination
with active Rho-GTPases can switch signaling between Rac
and Rho [21]. Furthermore, CRMP-2, a ROK substrate, is
phosphorylated by ROK in lipophosphatidic acid (LPA)-in-
duced growth cone collapse, but not in response to Sema3A
[22]. It appears that Sema3A impinges on Rac and Rho e¡ects
on the actin dynamics, resulting in growth cone motility and
alterations in axonal guidance cues [9].
Here using ROKK antibodies we have been able to detect
two CRMP family members associated with ROKK : CRMP-
2, and a novel splice variant of CRMP-1 with an extended
N-terminus. p80 CRMP-1 and CRMP-2 can form hetero-olig-
omers. The interaction of p80 CRMP-1 was mapped to the
kinase domain and resulted in inhibition of the ROK activity
towards other substrates. p80 CRMP-1 and CRMP-2 co-ex-
pression can counteract the e¡ect of Rho on neurite retraction
in SY5Y neuroblastoma cells, suggesting that these CRMP
proteins are modulators of Rho activity in neuronal morpho-
genesis.
2. Materials and methods
2.1. Construction of expression vectors
Full-length p80 cDNA was obtained by ¢rst performing a PCR
reaction of mouse cDNA based on the reported sequence of an
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EST clone (BM950288) encoding the N-terminus of an alternatively
spliced form of CRMP-1 (see Fig. 1B), using two adapter primers,
5P-CTAAGCTTCCGGAGACGGGGATGG-3P and 5P-GTCTCGA-
GGTCAACCGAGGCTGG-3P. The 2.1 kb PCR fragment was di-
gested with HindIII and XhoI and cloned into pXJ40-FLAG and
pXJ40-HA vectors for sequencing and expression studies. The 5P se-
quence encoding the p80 N-terminus (amino acids 1^127) was ob-
tained by PCR of the full-length p80 with primers 5P-
CTAAGCTTCCGGAGACGGGGATGG-3P and 5P-GGTCACTCT-
GGCCATTGTC-3P and subcloning of the BamHI/BalI fragment
into BamHI/SmaI sites of vector pGEX-4T1. pXJ40-FLAG- and
pXJ40-HA-tagged CRMP-2 and the mutant CRMP-2 (T555A),
pXJ40-HA ROKK11379, ROKK1543, ROKK9711379 and pGEX4T2-
myosin light chain 2 (MLC2) were obtained as previously described
[21,23].
2.2. Cell culture, transfection and cell staining
Neuroblastoma SY5Y cells were cultured in RPMI/MEM (1:1)
medium containing 10% fetal bovine serum (FBS). Subcon£uent
SY5Y cells plated on coverslips for 48 h were transfected with various
HA- or FLAG-tagged DNA constructs (1 Wg/ml) with E¡ectene trans-
fection reagent (Qiagen) according to the recommended protocol. Six-
teen hours after transfection, cells were ¢xed with 4% paraformalde-
hyde and stained with a combination of various primary antibodies:
anti-HA (12CA5; Boehringer Mannheim) or anti-FLAG, (M2; IBI).
Stained cells were analyzed with a Bio-Rad Radiance 2000 confocal
imager adapted to a Nikon microscope. COS-7 cells grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) with 10% FBS were sim-
ilarly transfected with various constructs. Twenty-four hours after
transfection, cell extract preparation and immunoprecipitations were
carried out as previously described [23]. PC12 cells grown in DMEM
with 10% FBS were treated with nerve growth factor (NGF) as pre-
viously described [6].
2.3. Preparation of antibodies, protein and enzymatic analyses
A⁄nity-puri¢ed antibodies against di¡erent domains of ROKK
were obtained as described previously [23]. Polyclonal antibodies
against the unique N-terminus of p80 CRMP-1 were obtained by
injecting the thrombin-cleaved polypeptide from glutathione S-trans-
ferase (GST) fusion protein into mice and puri¢ed through antigen
a⁄nity column for use in Western blotting, cell staining and immu-
noprecipitation assays. Kinase assays were carried out in bu¡er con-
taining 20 mM Tris^HCl pH 7.5, 75 mM NaCl and 10 mM MgCl2 as
previously described [23]. Analysis of tryptic peptides and phospho-
peptides was performed with a QSTAR mass spectrometer (Perkin
Elmer).
3. Results
3.1. Identi¢cation of p62 and p80 ROKK binding proteins
as CRMP-2 and a novel splice variant of CRMP-1
respectively
To identify and characterize potential binding proteins for
ROKK, we made use of the polyclonal antibodies of ROKK in
an immunoprecipitation assay. Two proteins of molecular
mass 62 and 80 kDa were the major components immunopre-
cipitated from brain extracts with the antibody against the
RhoA binding domain of ROKK (dBD-Ab; Fig. 1A [23]).
p62 in particular was readily phosphorylated when the immu-
noprecipitated products were subject to kinase assay (Fig. 1A,
left panel). The phosphorylation of p80 was much weaker
than for p62. We subjected these two proteins for mass spec-
trometry analysis and the data indicated that the p62 protein
is CRMP-2 whereas p80 is a novel splice form of CRMP-1.
This was further con¢rmed by Western blotting with antibody
for CRMP-2 and CRMP-1 (against the unique N-terminus,
see Section 2) that speci¢cally recognized the co-immunopre-
cipitated p62 and p80 respectively (Fig. 2A).
From the reported sequence of an EST cDNA (BM950288),
we obtained the mouse cDNA encoding the full-length protein
of p80 CRMP-1 by PCR. Sequence analysis of p80 cDNA
and comparison with the known p62 CRMP-1 con¢rm that
both p80 and p62 CRMP-1 are derived from the same gene
(Fig. 1B). The derived amino acid sequence of p80 CRMP-1
revealed an alternative splicing event from an upstream exon
(exon 1a) to generate p80 mRNA. It has been reported pre-
viously that the N-terminus of p62 CRMP-1 was derived from
exon 1 from chromosome 4p16 [24]. There is no sequence
similarity of this unique N-terminal sequence of p80 to any
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Fig. 1. Identi¢cation of p62 and p80 as major ROKK binding pro-
teins. A: Soluble rat brain extract was subjected to immunoprecipi-
tation by dBD-Ab and CC-Ab anti-ROKK antibodies with rabbit
IgG being used as control. Immunoprecipitates were separated on
SDS^PAGE and either stained with Coomassie blue (left panel) or
subjected to phosphorylation assay (right panel). The major bands
at 62 and 80 kDa are indicated. B: Amino acid sequence of the
mouse p80 CRMP-1 derived from DNA sequence revealed a splic-
ing event at the ¢rst exon. The spliced N-terminus of p80 CRMP-1
is boxed (a). This sequence was derived from a 5P exon (exon 1a)
from a human chromosome 4 gene (b). C: Tissue and developmen-
tal expression of p80 CRMP-1. (a) Soluble extracts (100 Wg) from
various tissues of adult rat or cell lines were resolved on SDS^
PAGE, transferred to polyvinylidene di£uoride ¢lter and immuno-
blotted with anti-p80 CRMP-1 antibody. For the developmental
pro¢le (b), rat brain cytosolic extracts (100 Wg) from di¡erent ages
were used. In panel c, PC12 cells with and without NGF treatment
(50 ng/ml) for 3 days were analyzed with either anti-p80 or anti-
GAP43 antibodies.
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known motif in the protein database. The sequence is rela-
tively proline-rich and may have a coiled structure at the ¢rst
50 amino acids of the N-terminus.
Like other CRMP proteins [25], the p80 CRMP-1 pro-
tein was expressed exclusively in the brain and cell lines of
neuronal origin (Fig. 1C, a). In rat brain, highest expression
was observed at around 5^10 days and at consistently lower
levels after day 20 (Fig. 1C, b); and similar to GAP43, p80
CRMP-1 expression can be induced by NGF in PC12 cells
(Fig. 1C, c).
3.2. p62 CRMP-2 and p80 CRMP-1 can form hetero-dimers
As only p62 CRMP-2 and p80 CRMP-1 were identi¢ed in
ROKK immunoprecipitates by both peptide sequencing and
immunoblotting analyses (Fig. 2A), it was of interest to see if
these two proteins can form oligomers as has been reported
for other CRMP proteins [26^28]. Both p80 CRMP-1 and
CRMP-2 were co-immunoprecipitated from rat brain extract
using antibody to p80 CRMP-1, indicating that these two
proteins exist as a dimer or higher molecular form (Fig.
2B). Furthermore, FLAG-tagged p80 CRMP-1 also co-immu-
noprecipitated with HA-tagged CRMP-2, supporting the no-
tion that these two proteins form hetero-dimers (Fig. 2C).
Furthermore, the catalytic domain of ROKK could phosphor-
ylate both immunoprecipitated p80 CRMP-1 and CRMP-2.
The phosphorylation towards CRMP-2 was consistently
weaker when phosphorylation was carried out with the co-
precipitated p80 and CRMP-2 (Fig. 2D). It is at present not
known if this is due to the lower amount of CRMP-2 co-
immunoprecipitated with p80-CRMP1.
3.3. p80 CRMP-1 interacted with the ROKK kinase domain
and inhibited the catalytic activity
To map the region of ROKK that interacted with p80
CRMP-1, we co-expressed the various regions of ROKK
with p80 CRMP-1. Only the full length and the kinase do-
main were detected in CRMP-1 immunoprecipitates, but not
the C-terminal region, indicating that p80 CRMP-1 interacted
with the kinase domain (Fig. 3A).
Likewise, when CRMP-2 and p80 CRMP-1 were co-ex-
pressed with the ROKK kinase domain, both CRMP proteins
were detected in the ROKK kinase immunoprecipitates (Fig.
3B). This gives further evidence that these CRMP proteins
can interact with the kinase domain of ROKK.
Furthermore, this interaction resulted in an inhibition of
the catalytic activity of ROKK, as the kinase co-precipitated
with p80 CRMP-1 was relatively inactive towards the exoge-
nous substrate MLC2 (Fig. 3C).
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Fig. 2. p80 CRMP-1 and p62 CRMP-2 can form hetero-dimers. A: Antibodies to CRMP-2 and p80 CRMP-1 speci¢cally recognized p62 and
p80 from immunoprecipitation by dBD-Ab. Immunoprecipitates from rat brain using either dBD-Ab or CC-Ab were probed with speci¢c anti-
body to CRMP-2 or p80 CRMP-1. Soluble cell extracts from COS-7 cells transfected with CRMP-2 or p80 CRMP-1 construct were used as
controls (arrows). The position of IgG bands is marked by an arrowhead. B: Co-immunoprecipitation of CRMP-2 with p80 CRMP-1 antibody
from rat brain extract. Soluble rat brain extract was subjected to immunoprecipitation with either p80 CRMP-1 antibody or mouse IgG as con-
trol. Immunoprecipitates were separated on SDS^PAGE and probed with anti-p80 CRMP-1 or anti-CRMP-2 antibody. Total extract (Ex) was
used for comparison. C: Co-immunoprecipitation of p80 CRMP-1 with CRMP-2 in over-expressed system. FLAG-tagged p80 CRMP-1 con-
struct was co-transfected with the HA-tagged CRMP-2 in COS-7 cells. Immunoprecipitations (IP) were carried out using anti-FLAG antibody
and immunoblotted (WB) with anti-FLAG or anti-HA antibody. Total lysate is shown for comparison (left panel). D: p80 CRMP-1 and
CRMP-2 are substrates of ROKK. Soluble extracts from COS-7 cells transfected with the various constructs were immunoprecipitated with
anti-FLAG antibody as described above and immunoblotted (WB) with anti-FLAG and anti-HA antibodies. Kinase assay on the immunopreci-
pitates was carried out using the catalytic domain of ROKK and [32P]ATP.
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3.4. p80 CRMP-1/CRMP-2 expression counteracts RhoA
activity on neurite retraction in SY5Y neuroblastoma cells
Activation of Rho kinase/ROK by RhoA in neuronal cells
caused neurite and cell body retraction in a variety of neuro-
nal cells [5^8]. In neuroblastoma SY5Y cells, over-expression
of RhoA also resulted in dramatic neurite and cell body re-
traction (Fig. 4A). The over-expression of p80 CRMP-1 and
CRMP-2 together signi¢cantly counteracted this RhoA activ-
ity. Interestingly, co-expression of CRMP-2 T555A (mutated
at the ROK phosphorylation site (T555) in CRMP-2 [22]) had
a more potent e¡ect on Rho inhibition (Fig. 4B). These results
indicated that the two CRMP proteins have a modulatory
e¡ect on RhoA activity in neuronal cells, probably as a result
of an inhibitory e¡ect on the RhoA-dependent ROKK cata-
lytic activity towards other substrates.
4. Discussion
Here we have demonstrated that ROKK can interact with
two CRMP proteins, CRMP-2 and p80 CRMP-1, a novel
splice variant. A previous study using a CRMP-2 antibody
has also demonstrated the association of an unidenti¢ed 190
kDa presumptive protein kinase [29]. It is possible that this
was ROKK. The e¡ective detection with antibody recognizing
the Rho binding region (dBD-Ab), but not with CC-Ab,
would suggest that only ROKK in the active state could in-
teract. The antibody dBD-Ab, but not CC-Ab, is capable of
inducing conformational changes of ROKK [23]. Interestingly,
CRMP-2 and p80 CRMP-1 can form hetero-oligomers and
this could be the functional form that interacted with
ROKK, when the kinase is in an active conformation (i.e.
induced by Rho-GTP binding or by interaction with the anti-
body dBD-Ab).
CRMP proteins are likely to form hetero-tetrameric struc-
tures [26] and CRMP-2 has been reported to bind CRMP-4
and CRMP-5 [27,28]. However, neither CRMP-4 nor the
shorter CRMP-1 isoform (p62 CRMP-1) was detectable in
our ROKK immunoprecipitates from rat brain (data not
shown). It has been reported that CRMP-2 was a substrate
of ROK/Rho kinase, phosphorylated in LPA-induced growth
cone collapse [22]. The morphological e¡ects of CRMP-2 in
association with dominant active Rac and Rho are also in£u-
enced by ROK phosphorylation [21]. We propose here that
the novel p80 CRMP-1 may be a functional partner of
CRMP-2. Furthermore, p80 CRMP-1 alone can bind ROKK
at the kinase domain and this resulted in inhibition of
the catalytic activity towards other substrates. It is possible
that p80 CRMP-1 and its partner CRMP-2 play a role as
direct modulators of RhoA and ROK signaling events.
Over-expression of p80 CRMP-1 and CRMP-2 was e¡ective
in counteracting RhoA-induced neurite retraction in neuro-
blastoma SY5Y cells, indicating that these proteins can inhibit
RhoA action on neuronal morphology. Interestingly, the en-
hanced inhibition of Rho-induced collapse elicited by the non-
Fig. 3. p80 CRMP-1 binds ROKK at the kinase domain and inhibits the catalytic activity. A: Mapping of the kinase domain of ROKK as
binding site for p80 CRMP-1. HA-tagged p80 CRMP-1 construct was transfected alone (lane 1), or co-transfected with either FLAG-tagged
ROKK11379 (lane 2), ROKK1543 (lane 3) or ROKK9711379 (lane 4). Immunoprecipitations were carried out with anti-HA antibody and immu-
noprecipitates were immunoblotted with anti-HA or anti-FLAG antibody. The arrowhead indicates the non-speci¢c band recognized by the
anti-HA antibody in total lysate and the asterisk marks the corresponding ROK protein immunoprecipitated by p80 CRMP-1. B: HA-tagged
ROKK1543 construct was expressed alone (lane 1) or co-expressed with FLAG-tagged p80 CRMP-1 and CRMP-2 (lane 2) in COS-7 cells. Im-
munoprecipitations were carried out with anti-HA antibody and immunoprecipitates were immunoblotted with anti-HA (top panel for
ROKK1543) or anti-FLAG antibody (bottom panel for p80 CRMP-1 and CRMP-2). C: Inhibition of ROKK catalytic activity upon p80
CRMP-1 binding. Soluble extract from COS-7 cells expressing HA-tagged ROKK1543 alone (left lane) or HA-tagged ROKK1543 and FLAG-
tagged p80 CRMP-1 (right lane) were subjected to immunoprecipitation (IP) with either anti-HA or anti-FLAG antibody. The immunoprecipi-
tates recovered were blotted (WB) and probed with anti-HA or anti-FLAG antibody. The kinase activities of the immunoprecipitates towards
GST-MLC2 were quanti¢ed and calculated as means and S.D. of the percentage of the ROKK kinase activity obtained from immunoprecipi-
tates of HA-ROKK1543 (as 100%).
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phosphorylatable CRMP-2 mutant (T555A) gives further sup-
port for the phosphorylation of CRMP-2 by ROK in this
regulatory event [22,23].
Over-expression of CRMP-2 in primary hippocampal neu-
rons was recently shown to produce multiple axons [30]. This
may well involve inhibition of the Rho pathway. Indeed p190
RhoGAP has been shown to participate in regulating axon
branch stability [31]. The relationship of CRMP-2 to Sema3/
plexin signaling is unclear. It remains to be seen if CRMP-2
requires eventual phosphorylation to free itself from the in-
teraction with ROKK complex and release the inhibitory e¡ect
on the kinase activity, thus providing a mechanism for switch-
ing Rho GTPase activity in response to Sema3A/Rac-medi-
ated and other guidance signals.
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Fig. 4. Over-expression of CRMP-2 and p80 CRMP-1 counteracts
the e¡ect of RhoA-induced neurite retraction in SY5Y neuroblasto-
ma cells. A: In (a) SY5Y cells transfected with pXJ40-FLAG p80
CRMP-1 and immunostained with anti-FLAG antibody showed
normal cell morphology. In (b) and (c), cells transfected with pXJ-
HA RhoA (wild-type) alone or together with pXJ40-FLAG-CRMP-
2/p80 CRMP-1 were ¢xed and stained with mouse anti-HA/FITC
anti-mouse, or co-stained with anti-HA/FITC and anti-FLAG/
TRITC; only anti-HA staining is shown. B: Statistical analysis of
the scores of SY5Y cells showing neurite retraction from transfec-
tion with various combinations of DNA constructs (as in A). The
scores are the means and S.D. from three or four separate experi-
ments.
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